VivoSeq
Ophthalmology

Ocular Inflammation

0

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Ocular Inflammation is an early-stage landscape with 0 programs across 3 companies. The most active players are Ocumension Therapeutics (Shanghai) Co., Ltd, Biogen, Tarsier Pharma.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

O

Ocumension Therapeutics (Shanghai) Co., Ltd

0 programs

PreclinicalBiogen logo

Biogen

0 programs

PreclinicalT

Tarsier Pharma

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed5 · 71%
Withdrawn1 · 14%
Recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
Recruiting·TTexas Retina Associates·Phase 3·NCT05486468·30 enrolled
Real-world Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy
Completed·—·N/A·NCT06902207·6,053 enrolled
Study of Dexycu in Treating Intraocular Inflammation
Completed·OOcumension Therapeutics (Shanghai) Co., Ltd·Phase 3·NCT06429306·285 enrolled
RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
Completed·Biogen logoBiogen·Phase 2·NCT02065375·109 enrolled
Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification
Completed·EEMS·Phase 2·NCT03580473·118 enrolled
A Study of TRS01 in Participants With Post-surgical Ocular Inflammation
Completed·TTarsier Pharma·Phase 1/2·NCT04222725·37 enrolled
Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection
Withdrawn·AAdapt Produtos Oftalmológicos Ltda.·Phase 3·NCT01721694

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)